Generex Biotechnology has signed a product licensing and distribution agreement with PMG Pharma for the registration, marketing, distribution and sale of its buccal insulin spray product Generex Oral-lyn in Chile.
Generex claims that its Oral-lyn is a safe, simple, fast, effective and pain-free alternative to subcutaneous injections of prandial insulin and is conveniently delivered to the membranes of the oral cavity by a simple asthma-like device with no pulmonary (lung) deposition.
Generex president and CEO Anna Gluskin said that this alliance is important as it opens up another key country in South America where diabetes is a highly prevalent condition.
PMG Pharma is a Chilean pharmaceutical corporation located in Santiago and focused in three therapeutic areas: diabetes, nephrology and an injectable product line sold in hospitals and pharmacies.